Sleep Disorders Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Cohort 1 (Non-small cell lung cancer – advanced, treated with immunotherapy)
Who might be able to join this trial:
- Adults aged 18 or older
- People with a confirmed diagnosis of non-small cell lung cancer (NSCLC), a common type of lung cancer
- People whose cancer is at an advanced or spread stage (stage IIIB–IV) and cannot be removed by surgery
- People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard scale (ECOG score of 0 or 1 — meaning fully active or able to carry out light work)
- People who have not yet received any treatment for their cancer
- People whose cancer has at least one measurable tumour, as defined by standard imaging guidelines
- People who are receiving a type of cancer treatment called a PD-1/PD-L1 inhibitor (an immunotherapy drug), either alone or combined with chemotherapy
- People who have given written consent to take part in the study
Who may not be able to join:
- People whose cancer has specific gene changes known as EGFR-sensitising mutations, ALK fusions, or ROS1 fusions
- People who have had another cancer diagnosis within the past 3 years
- People currently living with an acute or ongoing mental health condition
- People currently taking sleep medication
- People who have previously taken part in another clinical drug trial
- People who have brain metastases (cancer spread to the brain) that are causing symptoms
- People who are unable to complete questionnaire-based assessments
Cohort 2 (Small cell lung cancer – advanced, treated with immunotherapy)
Who might be able to join this trial:
- Adults aged 18 or older
- People with a confirmed diagnosis of small cell lung cancer (SCLC)
- People whose cancer is at an advanced or spread stage (stage III–IV) and cannot be removed by surgery
- People whose general health falls within a certain range (ECOG score of 0 or 1)
- People who have not yet received any treatment for their cancer
- People whose cancer has at least one measurable tumour, as defined by standard imaging guidelines
- People who are receiving a PD-1/PD-L1 inhibitor (an immunotherapy drug), either alone or combined with chemotherapy
- People who have given written consent to take part in the study
Who may not be able to join:
- People who have had another cancer diagnosis within the past 3 years
- People currently living with an acute or ongoing mental health condition
- People currently taking sleep medication
- People who have previously taken part in another clinical drug trial
- People who have brain metastases that are causing symptoms
- People who are unable to complete questionnaire-based assessments
Cohort 3 (Non-small cell lung cancer – earlier stage, receiving pre-surgery immunotherapy)
Who might be able to join this trial:
- Adults aged 18 or older
- People with a confirmed diagnosis of non-small cell lung cancer (NSCLC)
- People whose cancer is at a stage that may be removable by surgery (stage IB–IIIB)
- People whose cancer has at least one measurable tumour, as defined by standard imaging guidelines
- People who have not yet received any treatment for their cancer
- People who are receiving a PD-1/PD-L1 inhibitor (an immunotherapy drug), either alone or combined with chemotherapy, as treatment before planned surgery
- People whose heart and lung function is considered strong enough to tolerate surgery
- People who have given written consent to take part in the study
Who may not be able to join:
- People whose cancer has specific gene changes known as EGFR-sensitising mutations, ALK fusions, or ROS1 fusions
- People who have had another cancer diagnosis within the past 3 years
- People currently living with an acute or ongoing mental health condition
- People currently taking sleep medication
- People who have previously taken part in another clinical drug trial
- People who have brain metastases that are causing symptoms
- People who are unable to complete questionnaire-based assessments
Cohort 4 (Non-small cell lung cancer – early stage, treated with surgery)
Who might be able to join this trial:
- Adults aged 18 or older
- People with a confirmed diagnosis of non-small cell lung cancer (NSCLC)
- People whose cancer has been confirmed at an early stage (stage IA–IIIA)
- People for whom a tumour tissue sample is available
- People who have not yet received any treatment for their cancer
- People who are receiving surgery with the intent to fully remove the cancer
- People who have given written consent to take part in the study
Who may not be able to join:
- People who have had another cancer diagnosis within the past 3 years
- People currently living with an acute or ongoing mental health condition
- People currently taking sleep medication
- People who have previously taken part in another clinical drug trial
- People who are unable to complete questionnaire-based assessments
Cohort 5 (Non-small cell lung cancer – advanced, treated with targeted therapy)
Who might be able to join this trial:
- Adults aged 18 or older
- People with a confirmed diagnosis of non-small cell lung cancer (NSCLC)
- People whose cancer is at an advanced or spread stage (stage IIIB–IV) and cannot be removed by surgery
- People whose general health falls within a certain range (ECOG score of 0 or 1)
- People who have not yet received any treatment for their cancer
- People whose cancer has at least one measurable tumour, as defined by standard imaging guidelines
- People who are receiving a targeted therapy drug, either alone or combined with chemotherapy
- People whose cancer has a specific gene change (called a "driver gene mutation") that targeted therapy is designed to treat
- People who have given written consent to take part in the study
Who may not be able to join:
- People who have had another cancer diagnosis within the past 3 years
- People currently living with an acute or ongoing mental health condition
- People currently taking sleep medication
- People who have previously taken part in another clinical drug trial
- People who have brain metastases that are causing symptoms
- People who are unable to complete questionnaire-based assessments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 13574858332
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cohort 1 & 5: Progression-free survival (PFS); Cohort 2: Overall survival (OS); Cohort 3: Event-free survival (EFS); Cohort 4: Disease-free survival (DFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.